WEZEL PHARMA

WEZEL PHARMA has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €309,290 and a net result of €52,338. Equity is growing by ~17.7% per year across the filed fiscal years. Its solvency ranks better than 72% of 11293 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.4% (low).